Investing.com - BioLineRx reported on Wednesday second quarter earnings that beat analysts' forecasts and revenue that was inline with expectations.
BioLineRx announced earnings per share of $-0.1493 on revenue of $0.00. Analysts polled by Investing.com anticipated EPS of $-0.1667 on revenue of $0.00.
BioLineRx shares are up 9.92% from the beginning of the year and are trading at $2.770 , down-from-52-week-high.They are under-performing the Nasdaq which is up 13.75% from the start of the year.
BioLineRx shares lost 4.15% in intra-day trade following the report.
BioLineRx follows other major Healthcare sector earnings this month
BioLineRx's report follows an earnings beat by Abbott Labs on Thursday, July 22, 2021, who reported EPS of $1.17 on revenue of $10.22B, compared to forecasts EPS of $1.02 on revenue of $9.69B.
Merck ADR had beat expectations on Thursday, August 5, 2021 with second quarter EPS of $0.5304 on revenue of $5.77B, compared to forecast for EPS of $0.4897 on revenue of $5.63B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar